Another study has reported a decreased incidence of a variety of hematologic malignancies in type 2 diabetics using GLP-1 receptor agonists, including myeloid and lymphoid leukemias, non-Hodgkin's lymphoma, myelodysplastic syndromes, myeloproliferative neoplasms, monoclonal gammopathy, and multiple myeloma.13 The gene discussed is GLP1R; the disease is myeloproliferative disorder.